Kineta Reopens Enrollment For VISTA-101 Clinical Trial Evaluating KVA12123 In Patients With Advanced Solid Tumor Cancer
Portfolio Pulse from Benzinga Newsdesk
Kineta has reopened enrollment for its VISTA-101 clinical trial, which evaluates KVA12123 in patients with advanced solid tumor cancer. The trial includes a monotherapy arm and a combination arm with Merck's KEYTRUDA®. Kineta aims to complete enrollment by the end of 2024.
August 19, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kineta has resumed patient enrollment for its VISTA-101 trial, testing KVA12123 in advanced solid tumors, including a combination with Merck's KEYTRUDA®. Full enrollment is expected by the end of 2024.
The reopening of the VISTA-101 trial is a positive development for Kineta, as it indicates progress in their clinical research. The combination with Merck's KEYTRUDA® could enhance the trial's potential success, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Merck's KEYTRUDA® is being used in combination with Kineta's KVA12123 in the VISTA-101 trial for advanced solid tumors. This partnership could enhance the efficacy of KEYTRUDA® in new therapeutic areas.
The use of KEYTRUDA® in combination with KVA12123 in Kineta's trial could open new therapeutic avenues for Merck, potentially increasing the drug's market reach and boosting investor sentiment.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70